Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neuroblastoma 4Multiple Myeloma 2Vaccinia 1Transplant-Related Hematologic Malignancy 1Recurrence 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 30Rituximab 26Biopsy 23Specimen Handling 20Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 13Vincristine 11obinutuzumab 10Lenalidomide 10Etoposide 10Doxorubicin 10Bendamustine Hydrochloride 9pembrolizumab 7venetoclax 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5glofitamab 5acalabrutinib 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5copanlisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Granulocyte-Macrophage Colony-Stimulating Factor × 90 days × Clear all
NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡